about
Therapeutic drug monitoring for triazoles: A needs assessment review and recommendations from a Canadian perspectiveBinding of a Cyano- and Fluoro-containing Drug Bicalutamide to Cytochrome P450 46A1: UNUSUAL FEATURES AND SPECTRAL RESPONSEA Structural Snapshot of CYP2B4 in Complex with Paroxetine Provides Insights into Ligand Binding and Clusters of Conformational StatesComparison of the inhibitory profiles of itraconazole and cimetidine in cytochrome P450 3A4 genetic variantsPrediction of in vivo drug-drug interactions from in vitro data: impact of incorporating parallel pathways of drug elimination and inhibitor absorption rate constant.Mechanistic Modeling to Predict Midazolam Metabolite Exposure from In Vitro Data.Characterization of the mechanism of drug-drug interactions from PubMed using MeSH termsEffects of cytochrome p450 inhibitors on itraconazole and fluconazole induced cytotoxicity in hepatocytes.Accurate prediction of dose-dependent CYP3A4 inhibition by itraconazole and its metabolites from in vitro inhibition data.Assessment of algorithms for predicting drug-drug interactions via inhibition mechanisms: comparison of dynamic and static models.Metabolism of repaglinide by CYP2C8 and CYP3A4 in vitro: effect of fibrates and rifampicin.CYP2C8 but not CYP3A4 is important in the pharmacokinetics of montelukast.Dynamically simulating the interaction of midazolam and the CYP3A4 inhibitor itraconazole using individual coupled whole-body physiologically-based pharmacokinetic (WB-PBPK) modelsStereospecific metabolism of itraconazole by CYP3A4: dioxolane ring scission of azole antifungalsSingle-dose pharmacokinetics of intravenous itraconazole and hydroxypropyl-beta-cyclodextrin in infants, children, and adolescents.Population pharmacokinetic modeling of itraconazole and hydroxyitraconazole for oral SUBA-itraconazole and sporanox capsule formulations in healthy subjects in fed and fasted states.Preclinical monitoring of drug association in experimental chemotherapy of Chagas' disease by a new HPLC-UV method.Ritonavir is the best alternative to ketoconazole as an index inhibitor of cytochrome P450-3A in drug-drug interaction studies.Drug-drug interactions of antifungal agents and implications for patient care.Are circulating metabolites important in drug-drug interactions?: Quantitative analysis of risk prediction and inhibitory potency.Evaluation of 6β-hydroxycortisol, 6β-hydroxycortisone, and a combination of the two as endogenous probes for inhibition of CYP3A4 in vivo.Contribution of itraconazole metabolites to inhibition of CYP3A4 in vivo.Factors influencing the magnitude and clinical significance of drug interactions between azole antifungals and select immunosuppressants.Molecular pharmacokinetics of catharanthus (vinca) alkaloids.Posaconazole, a Second-Generation Triazole Antifungal Drug, Inhibits the Hedgehog Signaling Pathway and Progression of Basal Cell Carcinoma.Drugs as CYP3A probes, inducers, and inhibitors.The use of hepatocytes in evaluating time-dependent inactivation of P450 in vivo.Repurposing the Clinically Efficacious Antifungal Agent Itraconazole as an Anticancer Chemotherapeutic.Qualitative analysis of the role of metabolites in inhibitory drug-drug interactions: literature evaluation based on the metabolism and transport drug interaction database.The relative contributions of CYP3A4 and CYP3A5 to the metabolism of vinorelbine.Therapeutic drug monitoring (TDM) of antifungal agents: guidelines from the British Society for Medical Mycology.Management of drug and food interactions with azole antifungal agents in transplant recipients.Has the era of individualised medicine arrived for antifungals? A review of antifungal pharmacogenomics.Triazole antifungal agents drug-drug interactions involving hepatic cytochrome P450.In vitro-to-in vivo predictions of drug-drug interactions involving multiple reversible inhibitors.Understanding the critical disposition pathways of statins to assess drug-drug interaction risk during drug development: it's not just about OATP1B1.Liver injury associated with ketoconazole: review of the published evidence.Dealing with the complex drug-drug interactions: towards mechanistic models.Best practices for the use of itraconazole as a replacement for ketoconazole in drug-drug interaction studies.Functioning of drug-metabolizing microsomal cytochrome P450s: In silico probing of proteins suggests that the distal heme 'active site' pocket plays a relatively 'passive role' in some enzyme-substrate interactions
P2860
Q27009221-20189D77-1A60-49BF-9B30-7A52188BC5A2Q27675738-ABBC709F-CDA9-41A3-9B81-F315AE719C00Q27677947-D90F9BD4-5406-4C25-906F-462554640950Q28741680-24B023BB-5394-4302-9BAA-B690624DBE4BQ31012256-F374D8E7-5A12-467E-A539-6FFE76F46216Q31054926-6980F2CC-3D44-462F-9936-CDCBC8B0D504Q33579414-4741499C-68C5-4B76-AF90-D9DD18B60B09Q33601260-0416D164-FB18-48A2-BF4B-599E5685FD35Q33672805-86120384-8E12-48A8-B121-7BDC62B3F067Q34476096-875484A4-E0F5-43C1-AF29-A6CC38EAE453Q34561039-FB2D1751-D3C7-4B86-A6BD-5A22A6CD3B98Q35718619-0A4A74E6-739E-46A3-ACA4-955B6C53A778Q35753588-D85DCA9F-3BC1-44BF-B62C-CC7E2EF0D7A9Q35776638-080D6F53-AF71-4E3D-A651-51F85A2CBC8AQ35912756-16E74CB8-78E1-42EE-979B-8EC2F9315B31Q35960882-8FD040B6-DAB3-43EF-B9BE-8CC565E47B5DQ36018865-A77BE817-A1E3-4905-81B9-B2E2717AB872Q36072448-CB2E4CB3-1071-46E2-9EBB-8EB841CAD0C0Q36283721-FC0A9872-7AB6-44DA-968C-03568CA0D7F7Q36328417-1ADE6938-B79D-42EC-A47F-CFDF1A480C61Q36349377-B5A50BBF-6F45-45DB-8E5B-3054EC8852E0Q36369136-ECE66CB2-A6FF-4AD6-A080-D84F8552D164Q36662912-786AE9FC-EE1E-4D55-8EFB-F754D34137F4Q36795140-B349F27C-79D3-4B78-9C27-A1C18E5A30A9Q36917768-F63C2707-CC88-4DE4-9E0E-90E9BA204EB9Q37023996-7FDA653C-2262-4515-AC70-8866DDA2998BQ37106069-15054FD5-742D-4A79-8AF9-44B5FF5B3FFFQ37334087-12ADC926-E308-4D89-B452-8BA4B3EF9B75Q37392766-45D38E75-1330-401A-AD2C-64E633A5CC61Q37422747-51B8D524-8BC1-4203-96B9-B20CD2276426Q37688257-CB378D1A-BFD4-40B5-BEC7-CD668D1F87D6Q37775009-10B3CF7F-FA66-4E7A-A201-8995D85D6436Q37904672-87C937AE-3BF6-4985-9E27-5E335EA964FAQ37945308-38DE70CC-4FC8-4BC7-AF05-F5B238CD2D88Q37989979-83080AC6-5E53-49D3-9CB5-2F98CC9E0EEFQ38050686-6873B6CF-52DF-4F6E-BB2F-464ADAF79A09Q38248677-33B84C9D-B09E-429E-AE30-53D8E7471876Q38302225-506C7149-4DEE-40B6-A3FC-59AFE675D140Q38516237-FDFCA32B-EA4C-4183-A7E6-F4DAF8804520Q38571414-B23DD84A-5A37-44A0-A874-BE21893BC7BB
P2860
description
2004 nî lūn-bûn
@nan
2004 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2004 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
name
Role of itraconazole metabolites in CYP3A4 inhibition.
@ast
Role of itraconazole metabolites in CYP3A4 inhibition.
@en
Role of itraconazole metabolites in CYP3A4 inhibition.
@nl
type
label
Role of itraconazole metabolites in CYP3A4 inhibition.
@ast
Role of itraconazole metabolites in CYP3A4 inhibition.
@en
Role of itraconazole metabolites in CYP3A4 inhibition.
@nl
prefLabel
Role of itraconazole metabolites in CYP3A4 inhibition.
@ast
Role of itraconazole metabolites in CYP3A4 inhibition.
@en
Role of itraconazole metabolites in CYP3A4 inhibition.
@nl
P2093
P356
P1476
Role of itraconazole metabolites in CYP3A4 inhibition.
@en
P2093
Kenneth E Thummel
Kent L Kunze
Kyle E Allen
Nina Isoherranen
Wendel L Nelson
P304
P356
10.1124/DMD.104.000315
P577
2004-07-08T00:00:00Z